Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...
Vertex Pharmaceuticals (NASDAQ ... the company can now add to its list of approved drugs. On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results